{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:50:03Z","timestamp":1790394603189,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001646","name":"Robert Bosch Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13045-018-0657-6","type":"journal-article","created":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T09:03:24Z","timestamp":1536051804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-3348","authenticated-orcid":false,"given":"Simon","family":"Heine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Kleih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Gim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"B\u00f6pple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolors","family":"Colomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter E.","family":"Aulitzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"van der Kuip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Silkenstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,4]]},"reference":[{"key":"657_CR1","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62\u201371. https:\/\/doi.org\/10.1093\/annonc\/mdx223 .","journal-title":"Ann Oncol"},{"key":"657_CR2","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1172\/JCI61272","volume":"122","author":"P Jares","year":"2012","unstructured":"Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122:3416\u201323. https:\/\/doi.org\/10.1172\/JCI61272 .","journal-title":"J Clin Invest"},{"key":"657_CR3","doi-asserted-by":"publisher","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","volume":"23","author":"V Fern\u00e0ndez","year":"2005","unstructured":"Fern\u00e0ndez V, Hartmann E, Ott G, Campo E, Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol. 2005;23:6364\u20139. https:\/\/doi.org\/10.1200\/JCO.2005.05.019 .","journal-title":"J Clin Oncol"},{"key":"657_CR4","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/0092-8674(94)90540-1","volume":"79","author":"CJ Sherr","year":"1994","unstructured":"Sherr CJ. G1 phase progression: cycling on cue. Cell. 1994;79:551\u20135.","journal-title":"Cell"},{"key":"657_CR5","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1182\/blood-2006-04-016634","volume":"108","author":"M Marzec","year":"2006","unstructured":"Marzec M, Kasprzycka M, Lai R, Gladden AB, Wlodarski P, Tomczak E, et al. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood. 2006;108:1744\u201350. https:\/\/doi.org\/10.1182\/blood-2006-04-016634 .","journal-title":"Blood"},{"key":"657_CR6","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00109-016-1475-3","volume":"94","author":"S Qie","year":"2016","unstructured":"Qie S, Diehl JA. Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med. 2016;94:1313\u201326. https:\/\/doi.org\/10.1007\/s00109-016-1475-3 .","journal-title":"J Mol Med"},{"key":"657_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.yexcr.2017.09.031","volume":"360","author":"CA Valenzuela","year":"2017","unstructured":"Valenzuela CA, Vargas L, Martinez V, Bravo S, Brown NE. Palbociclib-induced autophagy and senescence in gastric cancer cells. Exp Cell Res. 2017;360:390\u20136. https:\/\/doi.org\/10.1016\/j.yexcr.2017.09.031 .","journal-title":"Exp Cell Res"},{"key":"657_CR8","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1158\/0008-5472.CAN-15-2347","volume":"76","author":"M Acevedo","year":"2016","unstructured":"Acevedo M, Vernier M, Mignacca L, Lessard F, Huot G, Moiseeva O, et al. A CDK4\/6-dependent epigenetic mechanism protects cancer cells from PML-induced senescence. Cancer Res. 2016;76:3252\u201364. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2347 .","journal-title":"Cancer Res"},{"key":"657_CR9","doi-asserted-by":"publisher","first-page":"15916","DOI":"10.1038\/ncomms15916","volume":"8","author":"S Vijayaraghavan","year":"2017","unstructured":"Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, et al. CDK4\/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun. 2017;8:15916. https:\/\/doi.org\/10.1038\/ncomms15916 .","journal-title":"Nat Commun"},{"key":"657_CR10","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.1158\/0008-5472.CAN-11-4139","volume":"72","author":"NE Brown","year":"2012","unstructured":"Brown NE, Jeselsohn R, Bihani T, Hu MG, Foltopoulou P, Kuperwasser C, Hinds PW. Cyclin D1 activity regulates autophagy and senescence in the mammary epithelium. Cancer Res. 2012;72:6477\u201389. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-4139 .","journal-title":"Cancer Res"},{"key":"657_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3892\/or.2017.5684","volume":"38","author":"Y Okada","year":"2017","unstructured":"Okada Y, Kato S, Sakamoto Y, Oishi T, Ishioka C. Synthetic lethal interaction of CDK inhibition and autophagy inhibition in human solid cancer cell lines. Oncol Rep. 2017;38:31\u201342. https:\/\/doi.org\/10.3892\/or.2017.5684 .","journal-title":"Oncol Rep"},{"key":"657_CR12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood.V126.23.339.339","volume":"23","author":"JK Doorduijn","year":"2015","unstructured":"Doorduijn JK, Minnema MC, Kersten MJ, Lugtenburg PJ, Schipperus MR, van Marwijk Kooy M, et al. Bortezomib maintenance therapy after induction with R-CHOP, ARA-C and autologous stem cell transplantation in newly diagnosed MCL patients, results of a multicenter phase II HOVON study. Blood. 2015;23:339.","journal-title":"Blood"},{"key":"657_CR13","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1412096","volume":"372","author":"T Robak","year":"2015","unstructured":"Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372:944\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1412096 .","journal-title":"N Engl J Med"},{"key":"657_CR14","doi-asserted-by":"publisher","first-page":"17682","DOI":"10.1074\/jbc.M110.189092","volume":"286","author":"AJ Smith","year":"2011","unstructured":"Smith AJ, Dai H, Correia C, Takahashi R, Lee S-H, Schmitz I, Kaufmann SH. Noxa\/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. J Biol Chem. 2011;286:17682\u201392. https:\/\/doi.org\/10.1074\/jbc.M110.189092 .","journal-title":"J Biol Chem"},{"key":"657_CR15","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","volume":"112","author":"R Oerlemans","year":"2008","unstructured":"Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112:2489\u201399. https:\/\/doi.org\/10.1182\/blood-2007-08-104950 .","journal-title":"Blood"},{"key":"657_CR16","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/blood-2010-02-269514","volume":"117","author":"P P\u00e9rez-Gal\u00e1n","year":"2011","unstructured":"P\u00e9rez-Gal\u00e1n P, Mora-Jensen H, Weniger MA, Shaffer AL, Rizzatti EG, Chapman CM, et al. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood. 2011;117:542\u201352. https:\/\/doi.org\/10.1182\/blood-2010-02-269514 .","journal-title":"Blood"},{"key":"657_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1476-4598-7-40","volume":"7","author":"DT Yang","year":"2008","unstructured":"Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer. 2008;7:40. https:\/\/doi.org\/10.1186\/1476-4598-7-40 .","journal-title":"Mol Cancer"},{"key":"657_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1158\/1078-0432.CCR-15-0987","volume":"22","author":"Z Chen","year":"2016","unstructured":"Chen Z, Teo AE, McCarty N. ROS-induced CXCR4 signaling regulates mantle cell lymphoma (MCL) cell survival and drug resistance in the bone marrow microenvironment via autophagy. Clin Cancer Res. 2016;22:187\u201399. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0987 .","journal-title":"Clin Cancer Res"},{"key":"657_CR19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1600-0609.2007.00995.x","volume":"80","author":"U Heider","year":"2008","unstructured":"Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, R\u00f6tzer S, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol. 2008;80:133\u201342. https:\/\/doi.org\/10.1111\/j.1600-0609.2007.00995.x.","journal-title":"Eur J Haematol"},{"key":"657_CR20","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1182\/blood-2010-04-278853","volume":"117","author":"G Rou\u00e9","year":"2011","unstructured":"Rou\u00e9 G, P\u00e9rez-Gal\u00e1n P, Mozos A, L\u00f3pez-Guerra M, Xargay-Torrent S, Rosich L, et al. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP\/Grp78. Blood. 2011;117:1270\u20139. https:\/\/doi.org\/10.1182\/blood-2010-04-278853 .","journal-title":"Blood"},{"key":"657_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.7497\/j.issn.2095-3941.2015.0013","volume":"12","author":"F-L Qu","year":"2015","unstructured":"Qu F-L, Xia B, Li S-X, Tian C, Yang H-L, Li Q, et al. Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth. Cancer Biol Med. 2015;12:401\u20138. https:\/\/doi.org\/10.7497\/j.issn.2095-3941.2015.0013 .","journal-title":"Cancer Biol Med"},{"key":"657_CR22","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/cam4.511","volume":"4","author":"L-L Zhao","year":"2015","unstructured":"Zhao L-L, Liu Y-F, Peng L-J, Fei A-M, Cui W, Miao S-C, et al. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib. Cancer Med. 2015;4:1754\u201366. https:\/\/doi.org\/10.1002\/cam4.511 .","journal-title":"Cancer Med"},{"key":"657_CR23","doi-asserted-by":"publisher","first-page":"27332","DOI":"10.18632\/oncotarget.2903","volume":"6","author":"VV Leshchenko","year":"2015","unstructured":"Leshchenko VV, Kuo P-Y, Jiang Z, Weniger MA, Overbey J, Dunleavy K, et al. Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma. Oncotarget. 2015;6:27332\u201342. https:\/\/doi.org\/10.18632\/oncotarget.2903 .","journal-title":"Oncotarget"},{"key":"657_CR24","doi-asserted-by":"publisher","first-page":"e1013","DOI":"10.1038\/cddis.2013.552","volume":"5","author":"MA Dengler","year":"2014","unstructured":"Dengler MA, Weilbacher A, Gutekunst M, Staiger AM, V\u00f6hringer MC, Horn H, et al. Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles\u2019 heel in mantle cell lymphoma. Cell Death Dis. 2014;5:e1013. https:\/\/doi.org\/10.1038\/cddis.2013.552 .","journal-title":"Cell Death Dis"},{"key":"657_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"T-C Chou","year":"1984","unstructured":"Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27\u201355. https:\/\/doi.org\/10.1016\/0065-2571(84)90007-4 .","journal-title":"Adv Enzym Regul"},{"key":"657_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/1476-4598-9-168","volume":"9","author":"S Haubeiss","year":"2010","unstructured":"Haubeiss S, Schmid JO, M\u00fcrdter TE, Sonnenberg M, Friedel G, van der Kuip H, Aulitzky WE. Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010;9:168. https:\/\/doi.org\/10.1186\/1476-4598-9-168 .","journal-title":"Mol Cancer"},{"key":"657_CR27","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1158\/1078-0432.CCR-10-3367","volume":"17","author":"MA Weniger","year":"2011","unstructured":"Weniger MA, Rizzatti EG, P\u00e9rez-Gal\u00e1n P, Liu D, Wang Q, Munson PJ, et al. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res. 2011;17:5101\u201312. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-3367 .","journal-title":"Clin Cancer Res"},{"key":"657_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","volume":"107","author":"P P\u00e9rez-Gal\u00e1n","year":"2006","unstructured":"P\u00e9rez-Gal\u00e1n P, Rou\u00e9 G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006;107:257\u201364. https:\/\/doi.org\/10.1182\/blood-2005-05-2091 .","journal-title":"Blood"},{"key":"657_CR29","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12885-015-1240-y","volume":"15","author":"S Bustany","year":"2015","unstructured":"Bustany S, Cahu J, Guardiola P, Sola B. Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathway. BMC Cancer. 2015;15:262. https:\/\/doi.org\/10.1186\/s12885-015-1240-y .","journal-title":"BMC Cancer"},{"key":"657_CR30","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.3324\/haematol.2011.040659","volume":"97","author":"DJ Medina","year":"2012","unstructured":"Medina DJ, Goodell L, Glod J, G\u00e9linas C, Rabson AB, Strair RK. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor \u03baB pathways. Haematologica. 2012;97:1255\u201363. https:\/\/doi.org\/10.3324\/haematol.2011.040659 .","journal-title":"Haematologica"},{"key":"657_CR31","doi-asserted-by":"publisher","first-page":"8750","DOI":"10.18632\/oncotarget.3275","volume":"6","author":"D Chiron","year":"2015","unstructured":"Chiron D, Dousset C, Brosseau C, Touzeau C, Ma\u00efga S, Moreau P, et al. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget. 2015;6:8750\u20139. https:\/\/doi.org\/10.18632\/oncotarget.3275 .","journal-title":"Oncotarget"},{"key":"657_CR32","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","volume":"67","author":"SD Demo","year":"2007","unstructured":"Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007;67:6383\u201391. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4086 .","journal-title":"Cancer Res"},{"key":"657_CR33","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","volume":"17","author":"S Arastu-Kapur","year":"2011","unstructured":"Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011;17:2734\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1950 .","journal-title":"Clin Cancer Res"},{"key":"657_CR34","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.febslet.2010.01.026","volume":"584","author":"T Aikawa","year":"2010","unstructured":"Aikawa T, Shinzawa K, Tanaka N, Tsujimoto Y. Noxa is necessary for hydrogen peroxide-induced caspase-dependent cell death. FEBS Lett. 2010;584:681\u20138. https:\/\/doi.org\/10.1016\/j.febslet.2010.01.026 .","journal-title":"FEBS Lett"},{"key":"657_CR35","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1158\/0008-5472.CAN-05-0676","volume":"65","author":"J-Z Qin","year":"2005","unstructured":"Qin J-Z, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 2005;65:6282\u201393. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0676 .","journal-title":"Cancer Res"},{"key":"657_CR36","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.celrep.2013.02.014","volume":"3","author":"K Brinkmann","year":"2013","unstructured":"Brinkmann K, Zigrino P, Witt A, Schell M, Ackermann L, Broxtermann P, et al. Ubiquitin C-terminal hydrolase-L1 potentiates cancer chemosensitivity by stabilizing NOXA. Cell Rep. 2013;3:881\u201391. https:\/\/doi.org\/10.1016\/j.celrep.2013.02.014 .","journal-title":"Cell Rep"},{"key":"657_CR37","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3324\/haematol.2010.022368","volume":"95","author":"M Baou","year":"2010","unstructured":"Baou M, Kohlhaas SL, Butterworth M, Vogler M, Dinsdale D, Walewska R, et al. Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica. 2010;95:1510\u20138. https:\/\/doi.org\/10.3324\/haematol.2010.022368 .","journal-title":"Haematologica"},{"key":"657_CR38","doi-asserted-by":"publisher","unstructured":"Yu L, Chen Y, Tooze SA. Autophagy pathway: cellular and molecular mechanisms. Autophagy. 2017:1\u20139. https:\/\/doi.org\/10.1080\/15548627.2017.1378838 .","DOI":"10.1080\/15548627.2017.1378838"},{"key":"657_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","volume":"12","author":"DJ Klionsky","year":"2016","unstructured":"Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12:1\u2013222. https:\/\/doi.org\/10.1080\/15548627.2015.1100356.","journal-title":"Autophagy"},{"key":"657_CR40","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1158\/1078-0432.CCR-10-2634","volume":"17","author":"RK Amaravadi","year":"2011","unstructured":"Amaravadi RK, Lippincott-Schwartz J, Yin X-M, Weiss WA, Takebe N, Timmer W, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011;17:654\u201366. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2634 .","journal-title":"Clin Cancer Res"},{"key":"657_CR41","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/bjh.14571","volume":"177","author":"E H\u00f6ring","year":"2017","unstructured":"H\u00f6ring E, Montraveta A, Heine S, Kleih M, Schaaf L, V\u00f6hringer MC, et al. Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma. Br J Haematol. 2017;177:557\u201361. https:\/\/doi.org\/10.1111\/bjh.14571 .","journal-title":"Br J Haematol"},{"key":"657_CR42","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1158\/0008-5472.CAN-03-3645","volume":"64","author":"SJ Kridel","year":"2004","unstructured":"Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004;64:2070\u20135. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-3645 .","journal-title":"Cancer Res"},{"key":"657_CR43","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.bbrc.2015.05.042","volume":"463","author":"J Liu","year":"2015","unstructured":"Liu J, Chang F, Li F, Fu H, Wang J, Zhang S, et al. Palmitate promotes autophagy and apoptosis through ROS-dependent JNK and p38 MAPK. Biochem Biophys Res Commun. 2015;463:262\u20137. https:\/\/doi.org\/10.1016\/j.bbrc.2015.05.042 .","journal-title":"Biochem Biophys Res Commun"},{"key":"657_CR44","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3892\/ijmm.2013.1530","volume":"32","author":"Y-Y Chen","year":"2013","unstructured":"Chen Y-Y, Sun L-Q, Wang B-A, Zou X-M, Mu Y-M, Lu J-M. Palmitate induces autophagy in pancreatic \u03b2-cells via endoplasmic reticulum stress and its downstream JNK pathway. Int J Mol Med. 2013;32:1401\u20136. https:\/\/doi.org\/10.3892\/ijmm.2013.1530 .","journal-title":"Int J Mol Med"},{"key":"657_CR45","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/jcp.24781","volume":"230","author":"M Park","year":"2015","unstructured":"Park M, Sabetski A, Kwan Chan Y, Turdi S, Sweeney G. Palmitate induces ER stress and autophagy in H9c2 cells: implications for apoptosis and adiponectin resistance. J Cell Physiol. 2015;230:630\u20139. https:\/\/doi.org\/10.1002\/jcp.24781 .","journal-title":"J Cell Physiol"},{"key":"657_CR46","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.febslet.2010.02.017","volume":"584","author":"M Komatsu","year":"2010","unstructured":"Komatsu M, Ichimura Y. Physiological significance of selective degradation of p62 by autophagy. FEBS Lett. 2010;584:1374\u20138. https:\/\/doi.org\/10.1016\/j.febslet.2010.02.017 .","journal-title":"FEBS Lett"},{"key":"657_CR47","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood-2003-11-3837","volume":"104","author":"K Specht","year":"2004","unstructured":"Specht K, Haralambieva E, Bink K, Kremer M, Mandl-Weber S, Koch I, et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood. 2004;104:1120\u20136. https:\/\/doi.org\/10.1182\/blood-2003-11-3837 .","journal-title":"Blood"},{"key":"657_CR48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91:101\u201319. https:\/\/doi.org\/10.1016\/j.mayocp.2015.11.007 .","journal-title":"Mayo Clin Proc"},{"key":"657_CR49","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1158\/0008-5472.CAN-06-4322","volume":"67","author":"P Gomez-Bougie","year":"2007","unstructured":"Gomez-Bougie P, Wuill\u00e8me-Toumi S, M\u00e9noret E, Trichet V, Robillard N, Philippe M, et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res. 2007;67:5418\u201324. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4322 .","journal-title":"Cancer Res"},{"key":"657_CR50","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/jnci\/djj334","volume":"98","author":"Y Ishii","year":"2006","unstructured":"Ishii Y, Pirkmaier A, Alvarez JV, Frank DA, Keselman I, Logothetis D, et al. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst. 2006;98:1238\u201347. https:\/\/doi.org\/10.1093\/jnci\/djj334 .","journal-title":"J Natl Cancer Inst"},{"key":"657_CR51","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/1878-0261.12072","volume":"11","author":"F-S Hsieh","year":"2017","unstructured":"Hsieh F-S, Chen Y-L, Hung M-H, Chu P-Y, Tsai M-H, Chen L-J, et al. Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4\/6-independent manner. Mol Oncol. 2017;11:1035\u201349. https:\/\/doi.org\/10.1002\/1878-0261.12072 .","journal-title":"Mol Oncol"},{"key":"657_CR52","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152","volume":"13","author":"J Kim","year":"2011","unstructured":"Kim J, Kundu M, Viollet B, Guan K-L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132\u201341. https:\/\/doi.org\/10.1038\/ncb2152 .","journal-title":"Nat Cell Biol"},{"key":"657_CR53","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/leu.2008.348","volume":"23","author":"E Drakos","year":"2009","unstructured":"Drakos E, Atsaves V, Li J, Leventaki V, Andreeff M, Medeiros LJ, Rassidakis GZ. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia. 2009;23:784\u201390. https:\/\/doi.org\/10.1038\/leu.2008.348 .","journal-title":"Leukemia"},{"key":"657_CR54","doi-asserted-by":"publisher","first-page":"5278","DOI":"10.1158\/1078-0432.CCR-12-0351","volume":"18","author":"L Rosich","year":"2012","unstructured":"Rosich L, Xargay-Torrent S, L\u00f3pez-Guerra M, Campo E, Colomer D, Rou\u00e9 G. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. Clin Cancer Res. 2012;18:5278\u201389. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0351 .","journal-title":"Clin Cancer Res"},{"key":"657_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s11658-016-0031-z","volume":"21","author":"WJ Liu","year":"2016","unstructured":"Liu WJ, Ye L, Huang WF, Guo LJ, Xu ZG, Wu HL, et al. p62 links the autophagy pathway and the ubiqutin-proteasome system upon ubiquitinated protein degradation. Cell Mol Biol Lett. 2016;21:29. https:\/\/doi.org\/10.1186\/s11658-016-0031-z .","journal-title":"Cell Mol Biol Lett"},{"key":"657_CR56","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/cdd.2012.16","volume":"19","author":"A Craxton","year":"2012","unstructured":"Craxton A, Butterworth M, Harper N, Fairall L, Schwabe J, Ciechanover A, Cohen GM. NOXA, a sensor of proteasome integrity, is degraded by 26S proteasomes by an ubiquitin-independent pathway that is blocked by MCL-1. Cell Death Differ. 2012;19:1424\u201334. https:\/\/doi.org\/10.1038\/cdd.2012.16 .","journal-title":"Cell Death Differ"},{"key":"657_CR57","doi-asserted-by":"publisher","first-page":"441","DOI":"10.14348\/molcells.2017.0115","volume":"40","author":"CH Ji","year":"2017","unstructured":"Ji CH, Kwon YT. Crosstalk and interplay between the ubiquitin-proteasome system and autophagy. Mol Cells. 2017;40:441\u20139. https:\/\/doi.org\/10.14348\/molcells.2017.0115 .","journal-title":"Mol Cells"},{"key":"657_CR58","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1242\/jcs.073874","volume":"124","author":"S Kaushik","year":"2011","unstructured":"Kaushik S, Bandyopadhyay U, Sridhar S, Kiffin R, Martinez-Vicente M, Kon M, et al. Chaperone-mediated autophagy at a glance. J Cell Sci. 2011;124:495\u20139. https:\/\/doi.org\/10.1242\/jcs.073874 .","journal-title":"J Cell Sci"},{"key":"657_CR59","doi-asserted-by":"publisher","first-page":"37098","DOI":"10.18632\/oncotarget.5776","volume":"6","author":"W D-w","year":"2015","unstructured":"D-w W, Z-j P, G-f R, G-x W. The different roles of selective autophagic protein degradation in mammalian cells. Oncotarget. 2015;6:37098\u2013116. https:\/\/doi.org\/10.18632\/oncotarget.5776 .","journal-title":"Oncotarget"},{"key":"657_CR60","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.4161\/auto.32135","volume":"10","author":"MJ Morgan","year":"2014","unstructured":"Morgan MJ, Gamez G, Menke C, Hernandez A, Thorburn J, Gidan F, et al. Regulation of autophagy and chloroquine sensitivity by oncogenic RAS in vitro is context-dependent. Autophagy. 2014;10:1814\u201326. https:\/\/doi.org\/10.4161\/auto.32135 .","journal-title":"Autophagy"},{"key":"657_CR61","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.4161\/auto.29264","volume":"10","author":"DT Vogl","year":"2014","unstructured":"Vogl DT, Stadtmauer EA, Tan K-S, Heitjan DF, Davis LE, Pontiggia L, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed\/refractory myeloma. Autophagy. 2014;10:1380\u201390. https:\/\/doi.org\/10.4161\/auto.29264 .","journal-title":"Autophagy"},{"key":"657_CR62","doi-asserted-by":"publisher","unstructured":"Chude CI, Amaravadi RK. Targeting autophagy in cancer: update on clinical trials and novel inhibitors. Int J Mol Sci. 2017; https:\/\/doi.org\/10.3390\/ijms18061279 .","DOI":"10.3390\/ijms18061279"},{"key":"657_CR63","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-017-0436-9","volume":"10","author":"GJ Yoshida","year":"2017","unstructured":"Yoshida GJ. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment. J Hematol Oncol. 2017;10:67. https:\/\/doi.org\/10.1186\/s13045-017-0436-9 .","journal-title":"J Hematol Oncol"},{"key":"657_CR64","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1083\/jcb.201508102","volume":"212","author":"AP Vel\u00e1zquez","year":"2016","unstructured":"Vel\u00e1zquez AP, Tatsuta T, Ghillebert R, Drescher I, Graef M. Lipid droplet-mediated ER homeostasis regulates autophagy and cell survival during starvation. J Cell Biol. 2016;212:621\u201331. https:\/\/doi.org\/10.1083\/jcb.201508102 .","journal-title":"J Cell Biol"},{"key":"657_CR65","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.15252\/embj.201490315","volume":"34","author":"T Shpilka","year":"2015","unstructured":"Shpilka T, Welter E, Borovsky N, Amar N, Mari M, Reggiori F, Elazar Z. Lipid droplets and their component triglycerides and steryl esters regulate autophagosome biogenesis. EMBO J. 2015;34:2117\u201331. https:\/\/doi.org\/10.15252\/embj.201490315 .","journal-title":"EMBO J"},{"key":"657_CR66","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1158\/1078-0432.CCR-16-1585","volume":"23","author":"W Zhou","year":"2017","unstructured":"Zhou W, Xu J, Li H, Xu M, Chen ZJ, Wei W, et al. Neddylation E2 UBE2F promotes the survival of lung cancer cells by activating CRL5 to degrade NOXA via the K11 linkage. Clin Cancer Res. 2017;23:1104\u201316. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1585 .","journal-title":"Clin Cancer Res"},{"key":"657_CR67","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/hmg\/ddm320","volume":"17","author":"JMM Tan","year":"2008","unstructured":"Tan JMM, Wong ESP, Kirkpatrick DS, Pletnikova O, Ko HS, Tay S-P, et al. Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum Mol Genet. 2008;17:431\u20139. https:\/\/doi.org\/10.1093\/hmg\/ddm320 .","journal-title":"Hum Mol Genet"},{"key":"657_CR68","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1083\/jcb.201005012","volume":"191","author":"BE Riley","year":"2010","unstructured":"Riley BE, Kaiser SE, Shaler TA, Ng ACY, Hara T, Hipp MS, et al. Ubiquitin accumulation in autophagy-deficient mice is dependent on the Nrf2-mediated stress response pathway: a potential role for protein aggregation in autophagic substrate selection. J Cell Biol. 2010;191:537\u201352. https:\/\/doi.org\/10.1083\/jcb.201005012 .","journal-title":"J Cell Biol"},{"key":"657_CR69","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.tcb.2017.01.001","volume":"27","author":"Z Deng","year":"2017","unstructured":"Deng Z, Purtell K, Lachance V, Wold MS, Chen S, Yue Z. Autophagy receptors and neurodegenerative diseases. Trends Cell Biol. 2017;27:491\u2013504. https:\/\/doi.org\/10.1016\/j.tcb.2017.01.001 .","journal-title":"Trends Cell Biol"},{"key":"657_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1207\/S15327914NC3701_1","volume":"37","author":"KA Conklin","year":"2000","unstructured":"Conklin KA. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer. 2000;37:1\u201318. https:\/\/doi.org\/10.1207\/S15327914NC3701_1.","journal-title":"Nutr Cancer"},{"key":"657_CR71","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3109\/10715762.2010.525233","volume":"45","author":"I Szumiel","year":"2011","unstructured":"Szumiel I. Autophagy, reactive oxygen species and the fate of mammalian cells. Free Radic Res. 2011;45:253\u201365. https:\/\/doi.org\/10.3109\/10715762.2010.525233 .","journal-title":"Free Radic Res"},{"key":"657_CR72","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fgene.2016.00204","volume":"7","author":"AG Eliopoulos","year":"2016","unstructured":"Eliopoulos AG, Havaki S, Gorgoulis VG. DNA damage response and autophagy: a meaningful partnership. Front Genet. 2016;7:204. https:\/\/doi.org\/10.3389\/fgene.2016.00204 .","journal-title":"Front Genet"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0657-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-018-0657-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0657-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T11:50:56Z","timestamp":1571831456000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-018-0657-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,4]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1186\/s13045-018-0657-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,4]]},"assertion":[{"value":"23 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The local ethics committee approved the collection of patient material as well as sample collection from healthy donors. The study was done in accordance with protocols approved by the Ethics Committee of the Hospital Cl\u00ednic (Barcelona, Spain) and the Robert-Bosch-Hospital (Stuttgart, Germany). All patients and donors signed an informed consent according to the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"112"}}